Skip to main content

Number Crunch Finding Funding

Premium

Michigan announced the recipients of $30 million from the Michigan Life Sciences Corridor — projects specifically involving genomics and proteomics garnered a good chunk of that. The news came on the heels of the state’s earlier announcement that it had slashed $12.5 million out of the group’s $45 million annual budget for 2003 and would lower 2004 funding even more, to $20 million.

Of the awards announced, GT rounded up those that appear most related to genomics, bioinformatics, and proteomics below.

Awardee Project Title Funding

Richard Everson,
Wayne State University

Streamlining genomics for personalized medicine

$2,354,979

Phil Andrews,
University of Michigan

Michigan Proteome Consortium

$2,084,012

Jack Preiss,
Michigan State University

Michigan Center for Structural Biology

$1,744,921

Tatiana Nikolskaya,
GeneGo

Platform technology for in silico reconstruction of disease states

$1,386,006

James Tiedje,
Michigan State University

GeneScreen: A low-cost and high-density DNA biochip for detecting up to 30,000 microorganisms

$1,137,449

Mark Hughes,
Wayne State University

Genomics Facility for the Life Sciences Corridor

$1,041,599

Mark Kielb,
DNA Software

Commercializing software for microarray and advanced PCR assay design

$364,000

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.